Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study.

Autor: Elsamany SA; Oncology Center, King Abdullah Medical City, Makkah, Saudi Arabia; Oncology Center, Mansoura University, Mansoura, Egypt. Electronic address: shereefmohamad@yahoo.com., Alghanmi H; King Abdullah Medical City, Makkah, Saudi Arabia., Albaradei A; King Abdullah Medical City, Makkah, Saudi Arabia., Abdelhamid R; Oncology Nurse, Oncology Center, King Abdullah Medical City, Makkah, Saudi Arabia., Madi E; Oncology Nurse, Oncology Center, King Abdullah Medical City, Makkah, Saudi Arabia., Ramzan A; Oncology Nurse, Oncology Center, King Abdullah Medical City, Makkah, Saudi Arabia.
Jazyk: angličtina
Zdroj: Breast (Edinburgh, Scotland) [Breast] 2022 Apr; Vol. 62, pp. 69-74. Date of Electronic Publication: 2022 Feb 01.
DOI: 10.1016/j.breast.2022.01.017
Abstrakt: Background: Adherence to long-term adjuvant hormonal therapy in hormonal receptors (HR)-positive breast cancer is really challenging and can affect the survival outcome. The present study aims to assess rate of compliance with hormonal therapy and possible predictive factors in a single institute in Saudi Arabia.
Patients &methods: We recruited patients with HR-positive breast cancer who presented to oncology outpatient clinics. Patients were assessed for compliance using a study questionnaire. Compliance was defined as taking ≥80% of prescribed doses of oral hormonal therapy. Different epidemiological, clinical, pathological and treatment data were checked in patients' medical records and correlated with compliance/interruption of hormonal therapy.
Results: Among the 203 recruited patients, 95.1% were compliant with hormonal therapy, while it was interrupted in 16.7% of patients, and 58.1% reported missing intake of hormonal pills. Age >50 years, having permanent job and higher education level were significantly associated with non-compliance in univariate analysis. On multivariate analysis, job status was the only independent predictor of non-compliance. The following parameters were significantly related to hormonal therapy interruption: marital status (single: 28.8% vs married patients: 12.6%, p = 0.01) and residence location (Makkah: 11.7% vs. outside Makkah: 25.3%, p = 0.019), lymphovascular invasion (LVI) (No: 20.9%, Yes: 7.8%, p = 0.025) and N0 tumours (compared to node-positive patients, p = 0.008). On multivariate analysis, marital status, residence location and N-stage, maintained significance relation with hormonal therapy interruption.
Conclusion: Compliance with hormonal therapy was high in the study cohort. Marital status, residence location, job status and N-stage may be related to interruption/compliance with hormonal therapy.
(Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: